Amylyx Pharmaceuticals (AMLX) News Today → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free AMLX Stock Alerts $1.93 -0.04 (-2.03%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAmylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conferencebusinesswire.com - May 8 at 9:00 AMAmylyx Pharmaceuticals (AMLX) Set to Announce Earnings on Thursdayamericanbankingnews.com - May 8 at 6:08 AMAmylyx Pharmaceuticals (AMLX) Scheduled to Post Earnings on Thursdaymarketbeat.com - May 3 at 10:33 AMAmylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024businesswire.com - May 2 at 9:00 AMAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Updateamericanbankingnews.com - May 2 at 1:18 AMAmylyx Pharmaceuticals (AMLX) Price Target Decreased by 17.36% to 4.34msn.com - April 17 at 8:02 PMAmylyx Pharmaceuticals: A Hold Rating Amidst Promising but Preliminary HELIOS Trial Resultsmarkets.businessinsider.com - April 12 at 9:19 AMHold Rating on Amylyx Pharmaceuticals Amid Uncertainties in Drug Efficacy and Market Prospectsmarkets.businessinsider.com - April 11 at 2:34 PMRobert W. Baird Lowers Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target to $3.00marketbeat.com - April 11 at 8:26 AMAmylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disordermsn.com - April 10 at 2:22 PMAmylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndromefinance.yahoo.com - April 10 at 9:22 AMAmylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndromebusinesswire.com - April 10 at 9:00 AMThe Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLXprnewswire.com - April 9 at 5:45 AMOptimistic Outlook for Amylyx Pharmaceuticals Inc with AMX0035’s Potential in Rare Diseasesmarkets.businessinsider.com - April 8 at 1:39 PM48 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyxstockhouse.com - April 8 at 1:39 PMThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)businesswire.com - April 8 at 12:00 PMAmylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024businesswire.com - April 8 at 9:00 AMAmylyx Pharmaceuticals Shifts Focus: Hold Recommendation Amidst R&D Pivot and Revenue Impactmarkets.businessinsider.com - April 8 at 8:39 AMUnveiling 6 Analyst Insights On Amylyx Pharmamarkets.businessinsider.com - April 8 at 8:39 AMHC Wainwright Reiterates Buy Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX)marketbeat.com - April 8 at 8:29 AMLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholdersprnewswire.com - April 8 at 5:45 AMAnalysts Just Slashed Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) EPS Numbersfinance.yahoo.com - April 6 at 2:33 PMAmylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint - Hagens Bermanmarkets.businessinsider.com - April 5 at 4:19 PMAMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud Lawsuitprnewswire.com - April 5 at 1:30 PMAmylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLXprnewswire.com - April 5 at 5:45 AMAmylyx Pharmaceuticals: Hold Rating Maintained Amidst Drug Discontinuation and Pipeline Developmentsmarkets.businessinsider.com - April 4 at 8:37 PMAMLX FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLXprnewswire.com - April 4 at 5:54 PMSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - AMLXprnewswire.com - April 4 at 2:40 PM5-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firmstockhouse.com - April 4 at 10:36 AMAmylyx withdraws ALS drug after trial fail, slashes headcountbizjournals.com - April 4 at 10:36 AMAmylyx to Pull ALS Drug From Market After Failed Trialbloomberg.com - April 4 at 10:36 AMUPDATE 1-Amylyx Pharma to remove ALS drug from US, Canada marketsfinance.yahoo.com - April 4 at 10:36 AMALS drug will be pulled from US market after study showed patients didn't benefitfinance.yahoo.com - April 4 at 10:36 AMSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyxprnewswire.com - April 4 at 10:15 AMAmylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the Marketbarrons.com - April 4 at 7:43 AMAmylyx Pharmaceuticals to remove ALS drug from US, Canada marketsreuters.com - April 4 at 7:12 AMAmylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategybusinesswire.com - April 4 at 7:00 AMShareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLXprnewswire.com - April 3 at 5:45 AMThe Gross Law Firm Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLXprnewswire.com - April 2 at 5:45 AMDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyxmarkets.businessinsider.com - April 1 at 10:22 PMLevi & Korsinsky Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLXprnewswire.com - April 1 at 5:45 AMAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Sees Significant Growth in Short Interestmarketbeat.com - March 31 at 1:21 PMAmylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO(R) ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint - Hagens Bermanstockhouse.com - March 31 at 12:46 PMAMYLYX PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLXprnewswire.com - March 29 at 10:45 PMSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyxprnewswire.com - March 29 at 10:40 AMThe Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholdersprnewswire.com - March 29 at 5:45 AMAmylyx Pharmaceuticals: Hold Rating Maintained Amidst Development Shifts and Trial Setbacksmarkets.businessinsider.com - March 28 at 2:09 AMROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLXprnewswire.com - March 27 at 6:31 PMApril 9, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against AMLXprnewswire.com - March 27 at 5:45 AMAMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud Lawsuitprnewswire.com - March 26 at 11:00 AM Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem. Protect your retirement savings from the inevitable devaluation of the dollar… AMLX Media Mentions By Week AMLX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMLX News Sentiment▼0.390.36▲Average Medical News Sentiment AMLX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMLX Articles This Week▼46▲AMLX Articles Average Week Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Nuvectis Pharma News Today FibroGen News Today Syros Pharmaceuticals News Today Sagimet Biosciences News Today PDS Biotechnology News Today DiaMedica Therapeutics News Today Repare Therapeutics News Today Karyopharm Therapeutics News Today Vistagen Therapeutics News Today Adicet Bio News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMLX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetry348 million Americans lives to END as we know it?The Oxford ClubThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.